Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
7.560
+0.470 (+6.63%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
November 18, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
November 13, 2024
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
MindMed to Participate in Upcoming Investor Conferences
November 13, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
November 07, 2024
From
Mind Medicine Inc.
Via
Business Wire
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
August 12, 2024
Via
Benzinga
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
October 24, 2024
From
Mind Medicine Inc.
Via
Business Wire
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...
Via
Talk Markets
MindMed Announces New Employee Inducement Grants
September 09, 2024
From
Mind Medicine Inc.
Via
Business Wire
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...
Via
Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
MindMed to Participate in September Investor Conferences
September 04, 2024
From
Mind Medicine Inc.
Via
Business Wire
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
August 24, 2024
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
August 15, 2024
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...
Via
Talk Markets
MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024
August 13, 2024
MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
From
Mind Medicine Inc.
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
August 09, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
August 09, 2024
From
Mind Medicine (MindMed) Inc.
Via
Business Wire
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 06, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
August 06, 2024
From
Mind Medicine Inc.
Via
Business Wire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
July 29, 2024
From
Mind Medicine Inc.
Via
Business Wire
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
July 17, 2024
From
Mind Medicine Inc.
Via
Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
3 Psychedelic Stocks to Ride to the Moon and Beyond
July 06, 2024
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.
Via
InvestorPlace
Exposures
Product Safety
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read
Via
Talk Markets
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
June 28, 2024
From
Mind Medicine Inc.
Via
Business Wire
Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M
June 26, 2024
The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain.
Via
Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.